Click to access mobile menu
Print
  • Share:
Skip Navigation LinksHome > Funding > ODS Research Portfolio > Grant Abstract

Notice: Historical Content
This is an archival or historical document and may not reflect current data.

Grant Abstract: PCPT and Select Cohorts: Core Infrastructure Support for Cancer Research

Grant Number: 5UM1CA182883-05
PI Name: Tangen
Project Title: PCPT and Select Cohorts: Core Infrastructure Support for Cancer Research

Abstract: Here we propose to evaluate the associations of dietary supplement use with risk of total, low- and high-grade prostate cancer in the Selenium and Vitamin E Cancer Trial (SELECT).11 The SELECT dietary supplement data, which includes 10-year history of supplement use at baseline, information on dose, and annual updates of supplement use, are a rich resource for understanding associations of dietary supplement use and prostate cancer risk. Although these data were collected during SELECT, they have not yet been used for analyses; thus, considerable resources are needed to clean the data and create complex derived dietary supplement use variables. Once cleaned, we will test our hypothesis that high doses of some individual dietary supplements may increase risk of prostate cancer. We will test this hypothesis with the following Specific Aims:

1) To evaluate associations of dietary supplement use with risk of total, low- and high-grade prostate cancer. We will focus on the following supplements: multivitamins, vitamin A, folic acid, fish oil (omega-3 fatty acids), calcium, zinc, vitamin C, vitamin D, and beta-carotene, and we will evaluate supplement use as a time-varying exposure. For the subset of dietary supplements associated with prostate cancer risk, we will also evaluate whether their use modifies the effects of the SELECT study supplements on prostate cancer risk.

Secondary aim:
1) To evaluate the associations of botanical, herbal and specialty supplements, including Co-enzyme Q10, Grapeseed, DHEA, Melatonin, SAM-e, Garlic, Saw Palmetto, Ginseng and Soy, with risk of total, low- and high-grade prostate cancer.



Back to Grants Page